PROJECT AIMS TO PROVE PLASTIC CAN BE FANTASTIC FOR PHARMACEUTICALS


using PET waste as a starting material for drug manufacturing, they hope to reduce reliance on petrochemicals and other non-renewable resources while creating new opportunities for sustainable innovation.


Beyond this transformative project, Impact Solutions is actively engaged in discovering novel methods to extract valuable chemicals from diverse waste sources and by-products. Their prior collaboration with IBioIC and seafood suppliers Farne Salmon, which led to the production of nylon from fish processing by- products, underscores their commitment to innovative, sustainable solutions.


Simon Rathbone, Development Manager at Impact Solutions said, “We are thrilled to be leading on this exciting project which could have a major influence in the way we produce pharmaceuticals here in the UK. By exploring the use of PET as part of the manufacturing method, we are not only addressing the environmental challenges posed by plastic waste but also creating a sustainable approach for producing essential medicines.”


This ground-breaking research aligns with the UK government's Life Science Vision, aiming to foster global competitiveness in life sciences manufacturing. Published in 2021, this visionary roadmap seeks to enhance resilience and reduce dependencies on international supply chains, as underscored by the disruptions experienced during the pandemic.


Liz Fletcher, Director of Business Engagement at IBioIC, said, “The exploration of PET plastics as a feed source for manufacturing medication represents a significant leap forward in bio- based medicines. The research also marks an important step in Scotland’s efforts to reach net zero, using enzymes and engineered biology for sustainable manufacturing. We look forward to witnessing the positive impact of this project and are pleased to continue our support for a company providing valuable alternatives for industrial plastic waste.”


Dr. Stephen Wallace, a UKRI Future Leaders Fellow and Senior Lecturer in Biotechnology at the University of Edinburgh, emphasizes the transformative potential of this platform


technology, “There’s potential for this to be a turning point for the pharmaceutical sector. While this project is focused on a specific type of plastic waste from the foil rolls, it’s a platform technology that could in the future be applied to alternative forms of waste PET from other sectors – if we get the foundations right.”


Scotland has set ambitious targets for achieving net-zero emissions, with plans to reach net zero by 2045, including interim targets of 75% by 2030 and 90% by 2040 through promoting circular economy principles. By demonstrating the feasibility and scalability of PET recycling for pharmaceuticals, this project could inspire other industries and sectors to adopt similar approaches and contribute to a more sustainable future.


Scottish researchers are leading the way in transforming plastic waste into life-saving neuropharmaceuticals through innovative PET recycling methods, this visionary project offers a glimpse into a more sustainable future for drug manufacturing and environmental stewardship.


The environmental impact of medicine prescribing “Medicines account for around 25% of carbon emissions in the NHS. If Scotland is to achieve net-zero, strategies for reducing carbon emissions from prescribing and medicines need to be tackled.” According to the Royal College of General Practitioners in a joint statement published in June 2022.


Commenting on the publication of the joint statement, Dr David Shackles, Joint Chair of RCGP Scotland said: “Radical action is required if Scotland is to reach its target of Net Zero and as individual prescribers, we have an important role to play in ensuring that our health service significantly reduces its carbon footprint.”


Pharmacy has an important role to play in promoting sustainable drug manufacturing practices. By advocating for environmentally responsible drug production and dispensing, pharmacy can help reduce waste, conserve resources, and improve patient outcomes. Pharmacy can also collaborate with other stakeholders such as manufacturers, regulators, policymakers, and patients to develop innovative solutions that enable economic, social, and environmental priorities.


scottishpharmacist.com 39


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48